INTERLEUKIN-13-BINDING PROTEINS Russian patent published in 2018 - IPC C07K16/24 A61K49/00 C07K16/46 A61K51/10 C12N15/63 C12P21/08 A61K39/395 C12N15/13 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Recombinant antibody or antigen-binding fragment thereof is described. This antibody binds IL-13, contains two variable domains, wherein one variable domain comprises the amino acid sequence of SEQ ID NO:80, and the other variable domain comprises the amino acid sequence of SEQ ID NO:81. In addition, said antibody comprises a human heavy chain constant region IgG1 comprising a hinge region comprising replacing leucine with alanine at position 234 (EU numbering) and the replacement of leucine with alanine at position 235 (EU numbering), also contains a constant region of light kappa of the human chain. This antibody blocks the binding of IL-13 to IL-13Rα1 and IL-13Rα2 and is capable of binding to a human IL-13 variant in which the arginine residue at position 130 in SEQ ID NO:1 replaced by the remainder of glutamine. Also described is a nucleic acid encoding a recombinant antibody or its antigen-binding fragment, replication and expression vectors containing such a nucleic acid. Host cells containing these vectors are described. Method for producing antibody or antigen-binding fragment thereof, capable of binding IL-13, including culturing the host cell. Also described is a pharmaceutical composition for treating IL-13 associated disorder that comprises effective amount of a recombinant antibody. Method is provided for treating a subject from a disorder in which the activity of IL-13 is deleterious, comprising the step of administering to the subject antibody or antigen-binding fragment thereof.

EFFECT: inventions are useful for detection of hIL-13 and for inhibiting activity of hIL-13, for example in a human suffering from disorder in which hIL-13 activity adversely affects health.

32 cl, 23 tbl, 2 ex